

by original claim 15; claim 22 is supported by original claim 16; and claims 23 and 24 are supported by original claim 18.

In the restriction requirement dated August 20, 2001, Paper No. 10, claims 13-15 and 16-18 were grouped together in Groups VI-X, with Group VI relating to monoclonal antibodies reacting with peptide subfragment SEQ ID NO:2. Applicants submit that claims 19-24 are within Group VI, which is elected for examination at this time.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version With Markings to Show Changes Made.**"

All of the claims remaining in the application are now clearly allowable. Favorable consideration and a Notice of Allowance are earnestly solicited.



00500

PATENT TRADEMARK OFFICE

Respectfully submitted,

Seed Intellectual Property Law Group PLLC

Jane E. R. Potter

Registration No. 33,332

(JEP:cew) #233706

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 1-18 have been canceled.

New claims 19-24 have been added.

(JEP:cew) #233706